## Consolidated Statement of Cash Flows

**Year Ended** *(In millions, except shares and per share data)*

|  | Jun 30, 2012 | Jun 30, 2011 | Jun 30, 2010 |
| --- | --- | --- | --- |
| **      Operations** |  |  |  |
|         Net Income | $16,978 | $23,150 | $18,760 |
| *          Retained earnings (deficit)* | $16,978 | $23,150 | $18,760 |
| **        Adjustments to reconcile net income to net cash from operations:** |  |  |  |
|           Goodwill impairment | $6,193 |  |  |
|           Depreciation, amortization, and other | $2,967 | $2,766 | $2,673 |
|           Stock-based compensation expense | $2,244 | $2,166 | $1,891 |
|           Net recognized gains on investments and derivatives | $200 | $362 | $208 |
|           Excess tax benefits from stock-based compensation | $93 | $17 | $45 |
|           Deferred income taxes | $954 | $2 | $(220) |
|           Deferral of unearned revenue | $36,104 | $31,227 | $29,374 |
|           Recognition of unearned revenue | $33,347 | $28,935 | $28,813 |
| **        Changes in operating assets and liabilities:** |  |  |  |
|           Accounts receivable | $1,156 | $1,451 | $2,238 |
|           Inventories | $(184) | $561 | $44 |
|           Other current assets | $(493) | $1,259 | $(464) |
|           Other long-term assets | $248 | $(62) | $223 |
|           Accounts payable | $(31) | $58 | $844 |
|           Other current liabilities | $410 | $(1,146) | $451 |
|           Other long-term liabilities | $174 | $1,294 | $1,407 |
|         Net Cash from Operating Activities | $31,626 | $26,994 | $24,073 |
| **      Financing** |  |  |  |
|         Short-term debt repayments, maturities of 90 days or less, net |  | $(186) | $(991) |
|         Proceeds from issuance of debt, maturities longer than 90 days |  | $6,960 | $4,167 |
|         Repayments of debt, maturities longer than 90 days |  | $814 | $2,986 |
|         Proceeds from Issuance of Common Stock | $1,913 | $2,422 | $2,311 |
|         Common stock repurchased | $5,029 | $11,555 | $11,269 |
|         Common stock cash dividends paid | $6,385 | $5,180 | $4,578 |
|         Excess tax benefits from stock-based compensation | $93 | $17 | $45 |
|         Other |  | $(40) | $10 |
|         Net Cash from Financing Activities | $(9,408) | $(8,376) | $(13,291) |
| **      Investing** |  |  |  |
|         Payments for Property, Plant and Equipment | $2,305 | $2,355 | $1,977 |
|         Acquisition of companies, net of cash acquired, and purchases of intangible and other assets | $10,112 | $71 | $245 |
|         Purchases of investments | $57,250 | $35,993 | $30,168 |
|         Proceeds from Maturities, Prepayments and Calls of Securities | $15,575 | $6,897 | $7,453 |
|         Sales of investments | $29,700 | $15,880 | $15,125 |
|         Securities lending payable | $394 | $(1,026) | $1,502 |
|         Net Cash from Investing Activities | $(24,786) | $(14,616) | $(11,314) |
|       Effect of exchange rates on cash and cash equivalents | $(104) | $103 | $(39) |
|       Net Change in Cash | $(2,672) | $4,105 | $(571) |
|       Cash and Cash Equivalents |  |  |  |
| *        Other investments* |  |  |  |
| *        Foreign government bonds* |  |  |  |
| *        Municipal securities* |  |  |  |
| *        Common and preferred stock* |  |  |  |
| *        U.S. government and agency securities* |  |  |  |
| *        Corporate notes and bonds* |  |  |  |
| *        Mutual funds* |  |  |  |
| *        Certificates of deposit* |  |  |  |
| *        Cash* |  |  |  |
| *        Mortgage-backed securities* |  |  |  |
| *        Commercial paper* |  |  |  |
|       Cash and Cash Equivalents |  |  |  |
| *        Other investments* |  |  |  |
| *        Foreign government bonds* |  |  |  |
| *        Municipal securities* |  |  |  |
| *        Common and preferred stock* |  |  |  |
| *        U.S. government and agency securities* |  |  |  |
| *        Corporate notes and bonds* |  |  |  |
| *        Mutual funds* |  |  |  |
| *        Certificates of deposit* |  |  |  |
| *        Cash* |  |  |  |
| *        Mortgage-backed securities* |  |  |  |
| *        Commercial paper* |  |  |  |